Platelet functions were studied in 16 patients with multiple myeloma (MM) and 4 with primary macroglobulinemia (PM). The fall in immunoglobulins on therapy was correlated with the status of platelet function. Effect of incubation of normal platelets with immunoglobulins derived from these patients on kaolin-induced platelet factor 3 (PF3) release was studied to elucidate the mechanism of platelet function defect. Results show increased bleeding time, absence or poor platelet adhesion and aggregation, poor PF3 availability and reduced total PF3 in platelets more consistently in PM but to a lesser extent in MM. Normalisation or partial reduction in globulins on therapy was associated with improvement in platelet functions. Incubation of normal platelets with immunoglobulins enhanced the kaolin-induced PF3 availability. It is suggested that in vivo platelet activation may bring about the PF3 release which subsequently manifests as poor PF3 availability and reduction in its total contents.

Keywords:
Altered platelet function, Multiple myeloma, Macroglobulinaemia
This content is only available via PDF.
© 1978 S. Karger AG, Basel
1978
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.